MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0003473
Samrudh Pharmaceuticals Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹101.47 Cr
▲ 16% YoY
Net loss · FY 2025
₹1.66 Cr
Net margin -1.6%
EBITDA · FY 2025
₹2.39 Cr
EBITDA margin 2.4%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹62 Lakh
Issued & subscribed
Open charges
₹103.44 Cr
Secured borrowings
Company age
35 yrs
Est. 1991
Employees · EPFO
348
Provident fund records
About Samrudh Pharmaceuticals Private Limited
Data last updated:
Samrudh Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 May 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1991PTC061667. Its GSTIN is 27AABCS4538H1ZA (Maharashtra).
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹62 Lakh. It is led by directors including Mohan Babulal Jain (Managing Director) and Sharad Himatlal Sheth (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at A/101 Prathana Apartments Plot No.15 Jawahar Nagar S.V. Road Goregaon (W), Mumbai, Maharashtra, India – 400062.
As per the financials filed for FY 2025, the company reported a revenue of ₹101.47 Cr, a growth of 16% compared to the previous year. For the same year it recorded a net loss of ₹1.66 Cr (net margin -1.6%) and EBITDA of ₹2.39 Cr (EBITDA margin 2.4%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 7% over five years.
The company has about 348 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹103.44 Cr on record. Court records list 2 cases involving the company, including 1 filed by the company and 1 filed against it. The company has 8 deals on record (5 secondary share transfers, 2 funding rounds, 1 rights issue), with disclosed funding of ₹1.71 Cr; the latest was in March 2022. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Makson Industries Private Limited with revenue of ₹101.93 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 196 overdue payments to 28 micro and small suppliers.
Samrudh Pharmaceuticals Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0003473). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website samrudhpharma.com.
Company details
CIN U24239MH1991PTC061667
Registration Number 061667
Incorporation Date 14 May 1991
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0003473
Key People
Mohan Babulal Jain Managing Director Sharad Himatlal Sheth Whole-Time Director Alok Sharad Sheth Whole-Time Director Recognitions & Rankings of Samrudh Pharmaceuticals
Contact details
Samrudh Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is samrudhpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressA/101 Prathana Apartments Plot No.15 Jawahar Nagar S.V. Road Goregaon (W), Mumbai, Maharashtra, India – 400062
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Samrudh Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Samrudh Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Samrudh Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Samrudh Pharmaceuticals Private Limited, buy the company report.
Financials of Samrudh Pharmaceuticals Private Limited
FY 2024 filings availableSamrudh Pharmaceuticals Private Limited reported revenue of ₹101.47 Cr (up 16% YoY) for FY 2025.
Revenue · FY 2025
₹101.47 Cr ▲ 16%
Net loss · FY 2025
₹1.66 Cr margin -1.6%
EBITDA · FY 2025
₹2.39 Cr margin 2.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 16%
3 years · compounded
▲ 5%
5 years · compounded
▲ 7%
EBITDA CAGR growth
1 year
▼ 36%
3 years · compounded
▼ 19%
5 years · compounded
▼ 7%
Revenue has grown at a compounded annual rate (CAGR) of 7% over five years, including 16% growth in the latest year. EBITDA fell 36% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.39 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.66 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.4% | ||||
| Net Profit Margin | -1.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Samrudh Pharmaceuticals Private Limited, buy the company report.
Board of directors of Samrudh Pharmaceuticals Private Limited
Samrudh Pharmaceuticals has 4 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sharad Himatlal Sheth | Whole-Time Director | 22 Apr 1992 | 34 Years 6 Months | Current |
| Manish Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Director | 08 Jan 2021 | 5 Years 9 Months | Current |
| Alok Sharad Sheth | Whole-Time Director | 01 Apr 1996 | 30 Years 7 Months | Current |
| Mohan Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Managing Director | 26 Mar 2018 | 8 Years 7 Months | Current |
Peer comparison
Samrudh Pharmaceuticals Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Makson Industries Private Limited | ₹101.93 Cr (FY 2018) | 4.0% | Mandideep, Madhya Pradesh, India | |||
| Maan Pharmaceuticals Ltd | ₹101.88 Cr (FY 2025) | -4.0% | Ahmedabad, Gujarat, India | |||
| Bueno Salud Care (India) Private Limited | ₹101.84 Cr (FY 2025) | 30.0% | Ahmedabad, Gujarat, India | |||
| Sachin Parenteral Private Limited | ₹101.7 Cr (FY 2025) | 82.0% | Aligarh, Uttar Pradesh, India | |||
| Pharma Impex Laboratories Pvt Ltd | ₹101.54 Cr (FY 2024) | 12.0% | Kolkata, West Bengal, India | |||
| Samrudh Pharmaceuticals Private Limitedthis company | ₹101.47 Cr (FY 2025) | -₹1.66 Cr | -1.6% | 16.0% | 348 | Mumbai, Maharashtra, India |
| Nabros Pharma Private Limited | ₹101.03 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Instapill Private Limited | ₹100.92 Cr (FY 2025) | 11.0% | Bangalore, Karnataka, India | |||
| Sotac Pharmaceuticals Limited | ₹100.88 Cr (FY 2025) | -3.0% | Sanand, Gujarat, India | |||
| Lake Chemicals Private Limited | ₹100.59 Cr (FY 2025) | -5.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Samrudh Pharmaceuticals Private Limited, buy the company report.
Auditor
Samrudh Pharmaceuticals Private Limited is audited by N I Parekh Shah & Associates LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| N I Parekh Shah & Associates LLP | FY 2024 | W100201 |
Shareholding
The shareholding of Samrudh Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Samrudh Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹103.44 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Jul 2012 | 10367563 | Bank of India | ₹14.9 Lakh | Open | |
| 31 Aug 2010 | 10240307 | Bank of India | ₹1 Cr | Open | |
| 06 Jul 2009 | 10240749 | Bank of India | ₹3 Cr | Open | |
| 07 Aug 2008 | 10120533 | Bank of India | ₹1.5 Cr | Open | |
| 21 Oct 2004 | 90152641 | Bank of India | ₹29.7 Cr | Open |
To see the full charge records of Samrudh Pharmaceuticals Private Limited, buy the company report.
Total charge records: 11 View all charges
Deals & funding
Samrudh Pharmaceuticals Private Limited has 8 deals on record (5 secondary share transfers, 2 funding rounds, 1 rights issue), with disclosed funding of ₹1.71 Cr; the latest was in March 2022.
Total deals
8
Secondary share transfers
5
Funding rounds
2
Rights issue
1
Disclosed funding
₹1.71 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2019 | Secondary share transfer | Undisclosed | Buyer: Mac-Chem Products (India) Private Limited , Naprod Lifesciences Private Limited, Miracalus Pharma Private Limited Seller: 3 individuals |
| Mar 2018 | Secondary share transfer | Undisclosed | Buyer: Naprod Lifesciences Private Limited, 2 individuals Seller: 4 individuals |
| Mar 2018 | Secondary share transfer | Undisclosed | Buyer: Naprod Lifesciences Private Limited, an individual Seller: 4 individuals |
| Mar 2018 | Rights issue | ₹6.5 Lakh | Investors: an individual |
To see the full deal history of Samrudh Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Samrudh Pharmaceuticals Private Limited has 2 court cases on record: 1 filed by Samrudh Pharmaceuticals, 1 filed against it. All cases are disposed.
Total cases
2
Filed by the company
1
Filed against the company
1
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 1 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, KALABURAGI, Karnataka | Criminal miscellaneous application | Filed by the company against an individual | Disposed |
| District court, Jammu, Jammu and Kashmir | Court case (Criminal Mislaneous) | Filed against the company by an individual | Disposed |
To see the full case history of Samrudh Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Samrudh Pharmaceuticals Private Limited was last rated by Crisil on 31 Aug 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 31 Aug 2020 |
To see the full credit ratings and regulatory alerts of Samrudh Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
Samrudh Pharmaceuticals Private Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 196 overdue payments to 28 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 28)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Hym Brothers | |||
| an individual supplier | |||
| an individual supplier | |||
| Dia Chemie |
To see the full MSME payment records of Samrudh Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Samrudh Pharmaceuticals Private Limited has a workforce of 348 employees on its EPFO records as of Mar 25, 2025, across 1 active EPFO establishment.
Employee count
348
Active EPFO establishments
1
Employee growth
5.78%
GST
Samrudh Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCS4538H1ZA | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Samrudh Pharmaceuticals Private Limited, buy the company report.
Recent activity
Samrudh Pharmaceuticals Private Limited has 12 board changes on record since 1992: 4 appointments and 8 cessations. The latest: Manish Babulal Jain ceased to be Additional Director on 26 Oct 2021.
AGM
Samrudh Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge with Bank Of India of Rs. 31.70 Cr registered on 03 Aug 1998 with Charge ID 90153516 was modified on 18 May 2024.
Filing
Samrudh Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Charges
A charge with Bank Of India of Rs. 29.70 Cr registered on 21 Oct 2004 with Charge ID 90152641 was modified on 26 Jul 2023.
Charges
A charge with Bank Of India of Rs. 29.70 Cr registered on 23 Jun 2003 with Charge ID 90152622 was modified on 26 Jul 2023.
Ceased
Manish Babulal Jain ceased to be Additional Director.
Ceased
Babulal Kesharimal Jain ceased to be Director.
Appointed
Manish Babulal Jain was appointed as Director.
Ceased
Harsha Sharad Sheth ceased to be Whole-Time Director.
Ceased
Jayendra Himmatlal Sheth ceased to be Whole-Time Director.
Ceased
Joseph Cosme Dsouza ceased to be Whole-Time Director.
Appointed
Mohan Babulal Jain was appointed as Managing Director.
19 earlier events are in the company report.
Frequently asked questions
Samrudh Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 May 1991 (35+ years old) and is registered under CIN U24239MH1991PTC061667.
Samrudh Pharmaceuticals has 4 current directors:
- Mohan Babulal Jain - Managing Director
- Sharad Himatlal Sheth - Whole-Time Director
- Alok Sharad Sheth - Whole-Time Director
- Manish Babulal Jain - Director
The latest financial statements of Samrudh Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Samrudh Pharmaceuticals is 27AABCS4538H1ZA, registered in Maharashtra.
The CIN (Corporate Identification Number) of Samrudh Pharmaceuticals is U24239MH1991PTC061667. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Samrudh Pharmaceuticals has 2 court cases on record: 1 filed by the company and 1 filed against it.
Samrudh Pharmaceuticals was incorporated on 14 May 1991, making it 35+ years old. It is registered with the Registrar of Companies, Mumbai.
Samrudh Pharmaceuticals has 8 deals on record (5 secondary share transfers, 2 funding rounds, 1 rights issue), with disclosed funding of ₹1.71 Cr; the latest was in March 2022.
The peers of Samrudh Pharmaceuticals by revenue are Makson Industries Private Limited, Maan Pharmaceuticals Ltd, Bueno Salud Care (India) Private Limited, Sachin Parenteral Private Limited, Pharma Impex Laboratories Pvt Ltd and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Manish Babulal Jain ceased to be Additional Director on 26 Oct 2021. Babulal Kesharimal Jain ceased to be Director on 08 Jan 2021. Manish Babulal Jain was appointed as Director on 08 Jan 2021. Samrudh Pharmaceuticals has 12 board changes on record in total.
Yes, Samrudh Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0003473).
Samrudh Pharmaceuticals has 14 MSME Form 1 returns on record between 2019 and 2024, listing 196 overdue payments to 28 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages